Protagonist Therapeutics vs Syndax Pharmaceuticals
Syndax Pharmaceuticals is the larger business, with $172m of revenue in fiscal 2025 against $46.0m for Protagonist Therapeutics (3.7 times as much). Syndax Pharmaceuticals grew faster (627.8% against -89.4%). Syndax Pharmaceuticals kept more of each dollar of sales as profit: a net margin of -165.6% against -282.8%. Protagonist Therapeutics carries less debt relative to equity (0.0% against 541.5%).
| Latest fiscal year | Protagonist TherapeuticsPTGX, 2025 | Syndax PharmaceuticalsSNDX, 2025 |
|---|---|---|
| Revenue | $46.0m | $172m |
| Revenue growth | -89.4% | 627.8% |
| Net income | −$130m | −$285m |
| Operating margin | -343.6% | -158.4% |
| Net margin | -282.8% | -165.6% |
| Return on equity | -20.2% | -161.8% |
| Free cash flow | $56.1m | −$323m |
| Cash | $128m | $135m |
| Total debt | $0 | $350m |
| Debt to equity | 0.0% | 541.5% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 132 | 298 |
| Market value | $9.14bn | $1.29bn |
| Price vs our value range | Above our value range | — |
| Moat score | 14 (Weak) | 8 (Weak) |
| Insider trades, 12 months | 0 buys, 37 sales | 0 buys, 10 sales |